A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Cancer of Unknown Primary (SiARa-CUP)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Sintilimab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms SiARa-CUP
- 09 Jan 2024 Planned End Date changed from 2 Jan 2024 to 31 Jan 2025.
- 09 Jan 2024 Planned primary completion date changed from 2 Jan 2024 to 31 Jan 2025.
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.